

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Caplacizumab for treating adults experiencing an  
episode of acquired thrombotic thrombocytopenic purpura**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes.

- a. Consultees noted that aTTP has a higher incidence in women compared to men. They stated this has a knock-on effect in terms of an impact on families
- b. Consultees noted that aTTP has a higher incidence in those of black ethnicity compared to those of a non-black ethnicity.
- c. Consultees noted that people of certain religions, such as Jehovah's Witness, are unable to accept donor blood products. While caplacizumab is expected to be used as an adjunct to plasma exchange therapy, attendees at the workshop suggested it may be used on its own for these patients.
- d. Consultees noted that people with an active HIV are at greater risk of developing aTTP than the general population
- e. Consultees noted that people with a cognitive impairment may be less likely to push for follow-up care and therefore are more likely to relapse
- f. Consultees noted that people with mobility issues may find it more difficult to attend follow up appointments

2.	What is the preliminary view as to what extent these potential equality issues need addressing by the committee?
	<ul style="list-style-type: none"> <li>a. It was considered unlikely that any recommendation would present barriers or limit access to these groups. Issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal.</li> <li>b. It was considered unlikely that any recommendation would present barriers or limit access to these groups. Issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal.</li> <li>c. This would need to be taken into consideration by the appraisal committee.</li> <li>d. It was considered unlikely that any recommendation would present barriers or limit access to these groups. Issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal.</li> <li>e. It was considered unlikely that any recommendation would present barriers or limit access to these groups.</li> <li>f. It was considered unlikely that any recommendation would present barriers or limit access to these groups.</li> </ul>

3.	Has any change to the draft scope been agreed to highlight potential equality issues?
	No change has been made to the scope.

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
	No change has been made to the matrix.

**Approved by Associate Director (name):** Nicole Elliott

**Date:** 8<sup>th</sup> August 2019